Antibody Polymer Conjugates (APCs) for Active Targeted Therapeutic Delivery

Area of Science:

• Nanomedicine
• Bioconjugation Chemistry
• Cancer Therapeutics

Background:

• Antibody drug conjugates (ADCs) show promise in targeted cancer nanomedicine.
• Current ADCs face limitations due to low drug-to-antibody ratio (DAR) and physiochemical instabilities.
• These limitations restrict the therapeutic efficacy of ADCs in cancer treatment.

Purpose of the Study:

• To design antibody polymer conjugates (APCs) as a modular strategy to overcome ADC limitations.
• To enhance the drug-to-antibody ratio (DAR) using polymer conjugation.
• To evaluate the targeted cell-killing efficacy of APCs against cancer cell lines.

Main Methods:

• Conjugation of polymer-based therapeutic molecules to antibodies to create APCs.
• Utilizing hydrophilic comonomers in polymers to mask hydrophobicity from high drug loading.
• Assessing cell targetability and selective cell killing in HER2 and EGFR-expressing cell lines.

Main Results:

• The APC platform successfully increased the drug-to-antibody ratio (DAR).
• APCs demonstrated effective cell targetability and selective killing of cancer cells.
• The platform's modularity allows attachment via different drug functionalities.

Conclusions:

• Antibody polymer conjugates (APCs) present a viable alternative to traditional ADCs.
• The APC platform offers improved DAR and targeted therapeutic delivery for nanomedicine.
• This strategy provides a foundation for next-generation active targeted nanomedicine in oncology.